Renin inhibition with aliskiren

Area of Science:

• Cardiovascular Pharmacology
• Drug Discovery and Development
• Hypertension Therapeutics

Background:

• Renin inhibition faced challenges, but molecular modeling and crystallography enabled new orally active inhibitors like aliskiren.
• The renin-angiotensin system (RAS) is a key target for cardiovascular and renal disease management.

Purpose of the Study:

• To evaluate the efficacy and characteristics of aliskiren, a novel oral renin inhibitor.
• To compare renin inhibition with other RAS blockade strategies.

Main Methods:

• Development of aliskiren through molecular modeling and X-ray crystallography.
• Clinical assessment of aliskiren's bioavailability, potency, half-life, and blood pressure-lowering effects in hypertensive patients.
• Comparison of biochemical consequences of renin inhibition versus ACE inhibition and AT1 receptor blockade.

Main Results:

• Aliskiren exhibits low bioavailability but high potency and a long half-life, allowing once-daily dosing.
• Once-daily aliskiren effectively lowers blood pressure in hypertension, comparable to ACE inhibitors, AT1 receptor blockers, and diuretics.
• Combination therapy with aliskiren enhances blood pressure reduction.

Conclusions:

• Renin inhibition presents a distinct biochemical profile compared to ACE inhibition or AT1 receptor antagonism.
• Aliskiren is a viable therapeutic option for hypertension, with potential for optimizing RAS blockade.
• Further research is needed to fully understand the benefits of complete RAS quiescence through renin inhibition.